202 related articles for article (PubMed ID: 38303608)
1. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY
Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992
[TBL] [Abstract][Full Text] [Related]
3. The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.
Klein DC; Lardo SM; Hainer SJ
Cancer Res Commun; 2024 Jan; 4(1):237-252. PubMed ID: 38126767
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).
Basuroy T; Dreier M; Baum C; Blomquist T; Trumbly R; Filipp FV; de la Serna IL
Pigment Cell Melanoma Res; 2023 Jan; 36(1):19-32. PubMed ID: 36112085
[TBL] [Abstract][Full Text] [Related]
5. The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A.
Sima X; He J; Peng J; Xu Y; Zhang F; Deng L
PLoS One; 2019; 14(9):e0222305. PubMed ID: 31504061
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Value of
Barma N; Stone TC; Carmona Echeverria LM; Heavey S
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944438
[TBL] [Abstract][Full Text] [Related]
7. Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway.
Zhou Y; Xu Q; Tao L; Chen Y; Shu Y; Wu Z; Lu C; Shi Y; Bu H
Clin Sci (Lond); 2020 Jun; 134(12):1457-1472. PubMed ID: 32514535
[TBL] [Abstract][Full Text] [Related]
8. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
[TBL] [Abstract][Full Text] [Related]
9. Advances in the role of SWI/SNF complexes in tumours.
Li Z; Zhao J; Tang Y
J Cell Mol Med; 2023 Apr; 27(8):1023-1031. PubMed ID: 36883311
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis reveals SMARCD1 is a potential biomarker and therapeutic target in skin cutaneous melanoma.
Chen J; Yu N; Ou S; Wang X; Li H; Zhu H
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11619-11634. PubMed ID: 37401939
[TBL] [Abstract][Full Text] [Related]
11. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma.
Lou W; Gao K; Xu C; Li Q
IUBMB Life; 2021 Nov; 73(11):1334-1347. PubMed ID: 34415102
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
14. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
15. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
16. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4.
Ahmed NS; Gatchalian J; Ho J; Burns MJ; Hah N; Wei Z; Downes M; Evans RM; Hargreaves DC
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34983841
[TBL] [Abstract][Full Text] [Related]
17. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
18. Spliceosomal disruption of the non-canonical BAF complex in cancer.
Inoue D; Chew GL; Liu B; Michel BC; Pangallo J; D'Avino AR; Hitchman T; North K; Lee SC; Bitner L; Block A; Moore AR; Yoshimi A; Escobar-Hoyos L; Cho H; Penson A; Lu SX; Taylor J; Chen Y; Kadoch C; Abdel-Wahab O; Bradley RK
Nature; 2019 Oct; 574(7778):432-436. PubMed ID: 31597964
[TBL] [Abstract][Full Text] [Related]
19. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
20. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
